Do appetitive gut hormones attenuate core behavioural components of addiction to prevent relapse in nicotine and alcohol addiction?

食欲肠道激素是否会减弱成瘾的核心行为成分,以防止尼古丁和酒精成瘾复发?

基本信息

  • 批准号:
    MR/M007022/1
  • 负责人:
  • 金额:
    $ 238.02万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2014
  • 资助国家:
    英国
  • 起止时间:
    2014 至 无数据
  • 项目状态:
    已结题

项目摘要

Smoking and alcohol abuse are major health burdens, with significant economic and social impacts on society. Once people stop smoking or drinking alcohol it is common for them to restart. There are only a few medications to help prevent people restarting, and they have limited success. New targets and more effective medications are needed. An additional problem after people stop smoking is that they commonly gain weight, which often hinders people trying to stop smoking, and can undo the health benefits gained by stopping smoking. Medications that prevent both weight gain and restarting smoking would therefore be most welcome.Behaviours that increase the risk of relapse to restarting smoking or drinking alcohol include: (i) increased craving for a drug or getting greater pleasure from taking it; (ii) being compulsive, that is doing the same actions repeatedly and being unable to inhibit oneself taking the drug; (iii) being impulsive, wanting things sooner rather than later, and engaging in risky behaviour; and (iv) increased sensitivity to stressful circumstances. These behaviours interact with each other, and involve co-ordinated activity of several overlapping brain regions including the frontal lobes, amygdala, dorsal and ventral striatum. New brain imaging techniques using functional MRI and computer tasks can measure these behaviours and associated brain activation. We have recently developed a sophisticated selection of such tests, as part of the MRC-funded ICCAM project, investigating how people with alcohol, cocaine and heroin abuse, may be helped by medications that block specific brain pathways e.g. dopamine. The tests involve winning or gambling money, looking at food, drug or unpleasant stressful pictures, trying to stop repetitive movements, and tests of memory and choice.This current proposal will use an identical series of tests to investigate a completely new way of modifying these behaviours in addiction by targeting hormones from the gut that are involved in appetite. It has long been known that similar regions are involved in the brain's processing of alcohol, drugs of abuse and food. Several drugs developed to treat addiction have had some benefits to help with weight loss in obesity and prevent binge eating. When we eat, the gut changes the release of hormones into the blood to signal to the brain how much and when we last ate, to reduce hunger and increase fullness. These include falls in the levels of the hormone acyl ghrelin from the stomach and increases in the hormone GLP-1 from the intestine. Medications based on these hormones are available or in development to treat obesity and diabetes. Gut hormones also alter how pleasurable food is to eat through actions on brain reward systems.Recently studies in animals have found that ghrelin increases and GLP-1 decreases the intake of alcohol, nicotine and other drugs of abuse. This raises the possibility that they may be targets to treat human addiction and prevent relapse after people stop smoking or drinking alcohol. They would also have the added benefit of aiding weight loss. Our proposed study will investigate such effects in humans for the first time by administering differing hormones or a dummy water injection on different days and seeing their effects on addictive behaviours using these brain imaging and computer tasks. Our Gut Hormones in ADDiction (GHADD) study will therefore investigate in healthy adults and those who have recently stopped smoking and abusing alcohol, if lowering/blocking acyl ghrelin or giving the gut hormone GLP-1 reduces the behaviours of reward sensitivity, impulsivity, compulsivity, and responses to negative emotions, and if either treatment reduces the desire for high-calorie foods and appetite.The results of this study will enable progress to clinical of whether drugs mimicking the actions of these hormones prevent relapse after people stop smoking or abusing alcohol, and explain how they work.
吸烟和酗酒是主要的健康负担,对社会造成重大的经济和社会影响。一旦人们停止吸烟或饮酒,他们通常会重新开始。只有少数药物可以帮助防止人们重新开始,而且它们的成功率有限。需要新的目标和更有效的药物。人们戒烟后的另一个问题是,他们通常会增加体重,这往往会阻碍人们戒烟,并可能抵消戒烟带来的健康益处。因此,既能防止体重增加又能防止重新吸烟的药物是最受欢迎的。增加重新吸烟或饮酒的风险的行为包括:(i)对药物的渴望增加或从服用药物中获得更大的乐趣;(ii)强迫性,即反复做同样的动作,无法抑制自己服用药物;(iii)强迫性,即无法抑制自己服用药物。(iii)冲动,想要尽早得到东西,以及从事危险行为;(iv)对压力环境的敏感性增加。这些行为相互影响,涉及几个重叠的大脑区域的协调活动,包括额叶,杏仁核,背侧和腹侧纹状体。使用功能性MRI和计算机任务的新大脑成像技术可以测量这些行为和相关的大脑激活。作为MRC资助的ICCAM项目的一部分,我们最近开发了一种复杂的测试选择,调查酒精,可卡因和海洛因滥用的人如何通过阻断特定大脑通路的药物(如多巴胺)获得帮助。这些测试包括赢钱或赌钱,看食物、药物或令人不快的压力图片,试图停止重复的动作,以及记忆和选择测试。目前的提议将使用一系列相同的测试来研究一种全新的方法,通过靶向肠道中与食欲有关的激素来改变成瘾中的这些行为。人们早就知道,类似的区域参与大脑对酒精、滥用药物和食物的处理。几种用于治疗成瘾的药物对减肥和防止暴饮暴食有一定的好处。当我们吃东西时,肠道会改变激素释放到血液中,向大脑发出信号,告诉我们上次吃了多少和什么时候吃,以减少饥饿感并增加饱腹感。这些包括胃中酰基生长激素释放肽水平的福尔斯下降和肠中GLP-1激素水平的增加。基于这些激素的药物可用于或正在开发中以治疗肥胖和糖尿病。肠道激素还通过对大脑奖励系统的作用来改变食物的愉悦程度。最近对动物的研究发现,生长激素释放肽增加,GLP-1减少酒精、尼古丁和其他滥用药物的摄入。这增加了它们可能成为治疗人类成瘾和防止人们停止吸烟或饮酒后复发的目标的可能性。他们也将有额外的好处,帮助减肥。我们提出的研究将首次通过在不同的日子施用不同的激素或虚拟水注射来研究人类的这种影响,并使用这些大脑成像和计算机任务来观察它们对成瘾行为的影响。因此,我们的成瘾性肠道激素(GHADD)研究将在健康成年人和最近戒烟和酗酒的人中进行调查,如果降低/阻断酰基生长激素释放肽或给予肠道激素GLP-1可以减少奖励敏感性,冲动性,强迫性和对负面情绪的反应,如果任何一种治疗方法都能降低对高血压的渴望,这项研究的结果将使临床进展,是否药物模仿这些激素的作用,防止复发后,人们停止吸烟或酗酒,并解释他们是如何工作的。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health.
  • DOI:
    10.1111/adb.12497
  • 发表时间:
    2018-01
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Badiani A;Berridge KC;Heilig M;Nutt DJ;Robinson TE
  • 通讯作者:
    Robinson TE
P.021 Comparison of food cue reactivity, eating behaviours, mood and impulsivity in obesity, ex-smokers and abstinent alcohol dependence
P.021 肥胖者、戒烟者和戒酒依赖者的食物线索反应、饮食行为、情绪和冲动的比较
  • DOI:
    10.1016/j.euroneuro.2020.09.025
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Herlinger K
  • 通讯作者:
    Herlinger K
Comparison of food cue reactivity and eating behaviours in obesity, ex-smokers and abstinent alcohol dependence.
肥胖者、戒烟者和戒酒依赖者的食物提示反应和饮食行为的比较。
  • DOI:
    10.1016/j.appet.2021.105548
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Herlinger K
  • 通讯作者:
    Herlinger K
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Nutt其他文献

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
致幻剂医疗化的知识差距:临床研究和监管方面
  • DOI:
    10.1016/j.nsa.2024.103938
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Drummond E;M.E. Liechti;K. Kuypers;David Nutt;Johan Lundberg;D. Stenbæk;G. Goodwin;G. Gründer;F. Butlen;Marion Haberkamp;Steffen Thirstrup;G. Knudsen
  • 通讯作者:
    G. Knudsen
FLUMAZENIL AND BENZODIAZEPINE WITHDRAWAL
氟马西尼和苯二氮卓戒断
  • DOI:
  • 发表时间:
    1987
  • 期刊:
  • 影响因子:
    0
  • 作者:
    David Nutt;M. Costello;J. Ball;P. Burnet;M. Ghatei;P. Mulderry;S. Bloom
  • 通讯作者:
    S. Bloom
Sedative antidepressants impair visual detection mechanisms in humans
镇静抗抑郁药会损害人类的视觉检测机制
  • DOI:
    10.1177/026988119601000209
  • 发表时间:
    1996
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    A. Weinstein;S. Wilson;J. Bailey;David Nutt
  • 通讯作者:
    David Nutt
Panic Attacks
惊恐发作
INCREASED SEXUAL FUNCTION IN BENZODIAZEPINE WITHDRAWAL
苯二氮卓戒断后性功能增强
  • DOI:
  • 发表时间:
    1986
  • 期刊:
  • 影响因子:
    0
  • 作者:
    David Nutt;A. Hackman;K. Hawton
  • 通讯作者:
    K. Hawton

David Nutt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Nutt', 18)}}的其他基金

MICA: [11C]BU99008 - A novel Positron Emission Tomography ligand for the Imidazoline2 Binding Site, First in human and initial patient group
MICA:[11C]BU99008 - 一种新型正电子发射断层扫描配体,用于咪唑啉 2 结合位点,首次出现在人类和初始患者组中
  • 批准号:
    MR/L01307X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
Can enhancing SWS improve daytime function in patients with CFS?
增强 SWS 能否改善 CFS 患者的日间功能?
  • 批准号:
    MR/M501591/1
  • 财政年份:
    2014
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
MICA: SRC inhibitors as potential antipsychotics: human testing with psilocybin
MICA:SRC 抑制剂作为潜在的抗精神病药:裸盖菇素的人体测试
  • 批准号:
    MR/K015192/1
  • 财政年份:
    2013
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
Can enhancing SWS improve daytime function in patients with CFS?
增强 SWS 能否改善 CFS 患者的日间功能?
  • 批准号:
    MR/J002852/1
  • 财政年份:
    2012
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
Psilocybin as a treatment for major depression
裸盖菇素用于治疗重度抑郁症
  • 批准号:
    MR/J00460X/1
  • 财政年份:
    2012
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
Neurotransmitters in Opiate and Alcohol Addiction
阿片类药物和酒精成瘾中的神经递质
  • 批准号:
    G1002226-E01/1
  • 财政年份:
    2011
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
New drugs for addiction: focus on attenuating core behavioural components of heroin, cocaine and alcohol addiction
新药成瘾:专注于减轻海洛因、可卡因和酒精成瘾的核心行为成分
  • 批准号:
    G1000018/1
  • 财政年份:
    2011
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
PET imaging of human brain gliosis using Imidazoline2 (I2) binding sites: potential biomarker for Alzheimer's disease
使用咪唑啉 2 (I2) 结合位点对人脑神经胶质增生进行 PET 成像:阿尔茨海默病的潜在生物标志物
  • 批准号:
    G0801501/1
  • 财政年份:
    2009
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant
PET imaging of human brain a2-adrenoceptors and noradrenaline release: biomarkers for brain diseases; Focus depression
人脑α2-肾上腺素受体和去甲肾上腺素释放的 PET 成像:脑部疾病的生物标志物;
  • 批准号:
    G0601461/1
  • 财政年份:
    2007
  • 资助金额:
    $ 238.02万
  • 项目类别:
    Research Grant

相似海外基金

A gut-brain interaction controlling reward learning
控制奖励学习的肠脑相互作用
  • 批准号:
    10677021
  • 财政年份:
    2022
  • 资助金额:
    $ 238.02万
  • 项目类别:
A gut-brain interaction controlling reward learning
控制奖励学习的肠脑相互作用
  • 批准号:
    10899004
  • 财政年份:
    2022
  • 资助金额:
    $ 238.02万
  • 项目类别:
GPR35 on Vagal Afferent Neurons as a Peripheral Drug Target for Treating Diet-Induced Obesity
迷走神经传入神经元上的 GPR35 作为治疗饮食引起的肥胖的外周药物靶点
  • 批准号:
    10315571
  • 财政年份:
    2021
  • 资助金额:
    $ 238.02万
  • 项目类别:
GPR35 on Vagal Afferent Neurons as a Peripheral Drug Target for Treating Diet-Induced Obesity
迷走神经传入神经元上的 GPR35 作为治疗饮食引起的肥胖的外周药物靶点
  • 批准号:
    10470747
  • 财政年份:
    2021
  • 资助金额:
    $ 238.02万
  • 项目类别:
Impact of gut microbiome composition on neuroendocrine signaling and feeding behavior in avoidant/restrictive food intake disorder
肠道微生物组组成对回避/限制性食物摄入障碍神经内分泌信号和进食行为的影响
  • 批准号:
    9813515
  • 财政年份:
    2018
  • 资助金额:
    $ 238.02万
  • 项目类别:
Gut to brain pathways regulating conditioned appetitive behavior
肠道到大脑的通路调节条件性食欲行为
  • 批准号:
    9763329
  • 财政年份:
    2018
  • 资助金额:
    $ 238.02万
  • 项目类别:
Microbiome-Vagal-Brain signaling: impact on the reward system and food intake
微生物组-迷走神经-大脑信号传导:对奖励系统和食物摄入的影响
  • 批准号:
    9166919
  • 财政年份:
    2016
  • 资助金额:
    $ 238.02万
  • 项目类别:
Microbiome-Vagal-Brain signaling: impact on the reward system and food intake
微生物组-迷走神经-大脑信号传导:对奖励系统和食物摄入的影响
  • 批准号:
    9321458
  • 财政年份:
    2016
  • 资助金额:
    $ 238.02万
  • 项目类别:
Higher-Order Neural Control of Food Intake
食物摄入的高阶神经控制
  • 批准号:
    10640909
  • 财政年份:
    2015
  • 资助金额:
    $ 238.02万
  • 项目类别:
Higher-Order Neural Control of Food Intake
食物摄入的高阶神经控制
  • 批准号:
    10458776
  • 财政年份:
    2015
  • 资助金额:
    $ 238.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了